 LOS ANGELES--BUSINESS WIRE--- CDXC collaboration--ChromaDex Corp. NASDAQ:CDXC announced today that it entered into a strategic supply agreement for Niagen with Ro, a healthcare-technology company. The agreement provides Ro with rights to ChromaDexs patented nicotinamide riboside ingredient Niagen, the sole active ingredient in Tru Niagen, for specially formulated Roman products. Ro has made great strides in a short period of time and we are looking forward to working with them to improve the well-being of t 